

HRDTrack Test

Homologous Recombination Deficiency (HRD)
status in tumor

Features

Comprehensive Content

- Statistically infer **Genome Aberration Score** from high quality genome-wide SNP markers representative of multiple ethnicities
- Identifies variants from complete coding regions & splice boundaries of **BRCA1 & 2 genes & 13 HRR genes**
- **CCNE1 amplification status**

Technologically advanced


- UMI-enabled library preparation to minimize errors
- Automated analysis & reporting
- Supports low input material

Clinically Validated & Accurate

- **Validated across ~200 samples** including reference standards, normal ovarian cancer samples and known clinical samples
- **Sensitivity - 96.3%, Specificity - 98.3%, Accuracy - 97.05%**
- Validated across FFPE tumor specimens with varied tumor content (10-90%); **>20% tumor content is required**
- Validated using different DNA input concentrations (10-200ng); **~30 ng of DNA input is required**
- **100% concordance** achieved with Myriad MyChoice HRD test

Validation

Samples	Concordance
Reference Standards (10)	100%
Healthy Ovarian Tissue (21)	100%
HRD Positive Clinical Samples (111)	96.39%
HRD Negative Clinical Samples (59)	98.3%
Myriad My Choice HRD (5)	100%



Test Details

Test Code	Test Name	Sample type	TAT
MGM1892	HRDTrack Test	Tumor tissue (>20% Tumour Content)	21 days

Expertise and Quality Matters



**Largest
CAP-accredited Lab**



350,000+ Exomes



10,000+ Clinicians



4,000+ Hospitals

Science is our DNA • Innovation is our Focus • Precision is our Expertise • Human Impact is our Vision



Genetic Counselling

FREE pre & post test genetic counselling with our expert and certified genetic counsellors



Talk to the Experts:

1800 103 3691

diagnostics@medgenome.com

www.medgenome.com

Follow us on
Linked

